Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO EV-to-EBIT is 5.00 as of Sep. 18, 2026, which is 50% below its 10-year median of 10.02. The stock has 1 warning sign investors should review. Among 112 Medical Diagnostics & Research companies, Invitro International ranks better than 91.96% on this metric.
Invitro International (OTCPK:IVRO) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Invitro International's Enterprise Value for the quarter that ended in Jun. 2026 was $0.93 Mil.
Invitro International's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Invitro International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Invitro International's EV-to-EBIT falls into.
Invitro International's current Enterprise Value is $0.35 Mil.
Invitro International's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a EV-to-EBIT of 5.00 as of Sep. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Invitro International and its competitors. This is 50% below median its historical median of 10.02. According to the industry distribution chart, Invitro International ranks #9 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 8%.
Is Invitro International's EV-to-EBIT too high?
Invitro International's current EV-to-EBIT of 5.00 is 50% below median its 10-year median of 10.02. The Medical Diagnostics & Research industry median EV-to-EBIT is 25.69. Invitro International's value of 5.00 is 80.5% below this industry median. Based on the distribution chart, Invitro International ranks #9 out of 112 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Invitro International's EV-to-EBIT compare to IDTA and FUNI?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #9 out of 112 companies for EV-to-EBIT. This places Invitro International in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 25.69. Invitro International's value of 5.00 is 80.5% below this benchmark. While the company's 10-year median is 10.02 vs. the industry median of 25.69, Invitro International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 25.69, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current EV-to-EBIT of 5.00 is 80.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 25.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current EV-to-EBIT is 5.00, which is 50% below median its own 10-year median of 10.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Fairly Valued. The stock's GF Value™ is $0.06, compared to a current price of $0.06 — trading right at its estimated fair value. The current EV-to-EBIT is 5.00, which is 50% below median its 10-year median of 10.02 and 80.5% below the Medical Diagnostics & Research industry median of 25.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Invitro International (IVRO), the current EV-to-EBIT is 5.00 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
